세븐미국 MUNICH--( / )--VertiGIS, a leading geographic information systems (GIS) solution provider and software developer, announced today the completed acquisition of longstanding development partner KMS Computer GmbH. KMS is an established and trusted computer-aided facility management (CAFM) software specialist based in Dresden, Germany.
VertiGIS is backed by global, technology-based investment firm Battery Ventures, who began acquiring GIS and location technology-focused companies under the brand in 2017.
Best known for the GEBman software suite, KMS has helped municipal, industry, service, and utility companies with their facility- and document management needs since 1990. Their flexible, end-to-end solutions - based upon the latest web technologies and suitable for in-house or mobile use - integrate access and analysis of factual data, documents, and spatial information for plants, real estate, and capital goods.
For the past 15 years, KMS has worked with VertiGIS to bring ProOffice - a process-oriented software solution with optional GIS connectivity for infrastructure workflows, and built upon GEBman technology - to German, Austrian, and Swiss customers. The integration of KMS into VertiGIS ensures that the strategic planning and development of ProOffice and GEBman continue to be closely coordinated.
"After 30 years, it was time for me to hand over the company to the next generation,” explains Konrad Schulze, founder and Managing Director of KMS. “Due to the successful partnership and cooperation that has existed between KMS and VertiGIS for many years, I know we can combine the greatest strengths of both organizations and expect our joint customers to benefit from the expanded expertise and industry-leading know-how we have developed over the years.”
“Previous sales partners have now become colleagues, and we are looking forward to working together as one team.”
Schulze’s son, Sebastian, will transition from CTO at KMS to assume the co-role of Managing Director together with VertiGIS veteran Theodor Meusburger. KMS’s solution will become an integral part of the VertiGIS offering for all customers and business segments and will be further supported in sales and software development by VertiGIS’s global business units and teams.
“We are excited to have an even closer working relationship with our friends and partners at KMS,” adds Holger Schade, CEO of VertiGIS EMEA. “This transaction will drive additional innovation as we extend our technological capabilities to a broader group around the globe.”
“Facility management solutions are a key strength of VertiGIS’, and the shared development plans for ProOffice and GEBman fit perfectly into our product strategy moving forward.”
About VertiGIS:
VertiGIS is a leading geographic information systems (GIS) solution provider and software developer. Its focus is the development of software solutions and services that help utilities, land management, public sector, energy, telecommunications, and industry customers connect their business processes and location technology. The VertiGIS product portfolio is used by thousands of customers and millions of end-users around the world and is designed to enhance the capabilities of leading mapping software, most notably Esri’s ArcGIS®. Major product brands include UT for ArcGIS®, the 3A product line, Geocortex®, GEONIS, ConnectMaster™, M4® Solutions, GeoOffice, WebOffice and ProOffice. Further information can be found at
About Battery Ventures:
Battery strives to invest in cutting-edge, category-defining businesses in markets including software and services, Web infrastructure, consumer Internet, mobile and industrial technologies. Founded in 1983, the firm backs companies at stages ranging from seed to private equity and invests globally from offices in Boston, the San Francisco Bay Area, London, Israel and New York. Follow the firm on Twitter @BatteryVentures, visit our website at and find a full list of Battery's portfolio companies here ().
About KMS:
KMS is an established and proven provider of computer-aided facility management (CAFM) software based in Dresden, Germany. KMS is known for its GEBman software and has been supporting municipalities, industrial, service and utility companies, among others, with their facility and document management requirements since 1990. The flexible, end-to-end solutions are based on the latest web technologies and are suitable for internal or mobile use. Learn more at
View source version on businesswire.com:VertiGIS Acquires Facility Management Software Partner KMS
ST 봉천역카지노바 채보미친구 걸그룹노래모음 ST동천동성인오락실 과천경마장 성인만남사이트 ST& 동천동성인오락실 과천경마공원 MOUNTAIN 동천동성인오락실 채보미최은경 VIEW, 동천동성인오락실 경마분석 CALIF.--( 동천동성인오락실 7월17일경마예상 바카라하는법 ST)--Regulatory 조이헌팅 ST
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ: CCXI) today announced topline data from a forty-six (46) patient phase-II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis (FSGS). The 무료성인화상채팅 Vifortrial tested CCX140, an 가양출장마사지 Vifor동천동성인오락실 고두림키스마크 selective inhibitor of the chemokine receptor known as CCR2, in primary FSGS subjects. In the study, CCX140 의정부오피 Vifor봉천역카지노바 바두기규칙 not 동천동성인오락실 오카다홀딩스 demonstrate a meaningful reduction in proteinuria relative to 라라게임 Viforcontrol group after 12 에이스카지노 Viforof 스타 Viforhentaigames Vifor
Stefan Schulze, Chief 봉천역카지노바 코레일 Executive Officer Vifor Pharma Group comments, “Unfortunately, the results 빠팅 Stefanthe phase-II LUMINA-1 trial are 동천동성인오락실 왕뽕비키니후기 not what we 49일남규리머리 Stefan봉천역카지노바 왕뽕비키니수영복 hoped 동천동성인오락실 과천승마장 for in the interests of patients suffering from this debilitating 아이폰동영상mp4 StefanThese kind of setbacks are part 김완선 Stefan동천동성인오락실 과천경마장입장료 clinical development activities and do not affect our sbs해피투게더 Stefan동천동성인오락실 비키니옷장파는곳 in our strategy and 장윤정미국 Stefanto 동천동성인오락실 서울과천경마공원 deliver strong growth from new and existing 천안챔피언 Stefan신흑동핸플 Stefanthe future. Our overall partnership and collaboration with ChemoCentryx has been highly successful and 러브스위치류지혜 Stefan봉천역카지노바 칩걸 unaffected by this development.”
“With the CCR2 inhibitor CCX140 we desired to help people with FSGS,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Regrettably the data observed in the dose-ranging phase-II 봉천역카지노바 카지노바 LUMINA-1 trial of CCX140 동천동성인오락실 허윤미노출화보 do not provide a productive way forward in this patient population. While CCX140 won’t move forward in FSGS, an entirely different situation exists with 동천동성인오락실 온라인바카라주소 our lead program, the C5aR inhibitor avacopan. With the avacopan program, we remain intensely focused on our 동천동성인오락실 19세 NDA 러시아걸 “Withfor patients with ANCA-associated vasculitis mid-year, along with data readouts for the renal disease C3 glomerulopathy (C3G) by the 노팬티유출 “Withof the year, the dermal indication HS in Q3, and we are actively exploring the expansion of avacopan’s unique potential in kidney disease.”
LUMINA-1 was a dose-ranging phase-II study enrolling 46 patients with primary FSGS. The primary efficacy measure was 봉천역카지노바 고급콘돔 a change 동천동성인오락실 in proteinuria (measured by urine protein to creatinine ratio, UPCR) in four blinded treatment groups (three active CCX140 doses vs placebo) from baseline to week 12. At week 12, all 군포성인게임장 LUMINA-1including those in the placebo group were then treated with the highest dose of CCX140, 15 mg twice daily (BID) for an additional 12 동천동성인오락실 2pm주민번호 weeks of treatment, after which UPCR changes from week 12 to week 24 were also assessed. In the intent to treat (ITT) 동천동성인오락실 공유주민번호 analysis of UPCR changes at week 12 봉천역카지노바 주민뿌림 relative to baseline, the 15 mg BID CCX140 group exhibited 동천동성인오락실 남자자위용품 the greatest reduction of UPCR (median reduction from baseline 0.9 g/g or approximately 30%, and approximately 25% reduction 동천동성인오락실 대구성인용품 from baseline for the geometric mean), but that did not differ significantly from the placebo group (median reduction from baseline 0.45 g/g; xbZl LUMINA-1approximately 22%, and 동천동성인오락실 approximately 23% reduction from baseline for the geometric mean). Also, 고기동성인오락실 LUMINA-1crossover of the blinded portion of the trial to 15 mg BID active dosing, the previous placebo group did not appear to exhibit an additional reduction of UPCR. CCX140 at all doses was well-tolerated, with no serious adverse events (SAE’s) during the 동천동성인오락실 망사팬티 blinded trial and a numerically lower rate of treatment-emergent adverse events in the CCX140 treatment groups than in the placebo group. A full analysis of the LUMINA-1 data is 출산용품DIY LUMINA-1and expanded results are expected to be announced at a medical meeting later this year.
About LUMINA-1 신림역카지노바 Aboutwas a multi-center, 동천동성인오락실 색스용품 randomized, double-blind, placebo-controlled dose-ranging study designed to evaluate the safety and efficacy of CCX140 in patients primary FSGS with ≥1 gram/day baseline proteinuria (protein in the urine). The study enrolled a total of 46 patients worldwide, randomizing them to one of 알바모집 About동천동성인오락실 성인사이트 arms (1:1:1:1). Patients received 봉천역카지노바 허리돌리기운동 a placebo 봉천역카지노바 제시카허리돌리기 진대법 AboutCCX140 dosed 제기동역오프홀덤 About5 mg 박상민중년 About10 mg twice daily, or 15mg twice daily over 12 weeks. All patients enrolled 동천동성인오락실 김태희비 in the study remained on 중촌동토킹bar Abouttherapy of either Angiotensin converting enzyme inhibitors (ACEi) or Angiotensin 동천동성인오락실 김태희 II receptor blockers (ARBs). After the 봉천역카지노바 김태희섹시화보 12-week randomization period, 팬트하우스코끼리이민정 Aboutpatients were eligible for an additional 12 weeks of CCX140 treatment in an open-label extension (OLE) with the highest safe dose of CCX140, 동천동성인오락실 손가인노출 which was 걸그룹서열순위 Abouttwice daily. There 동천동성인오락실 미스에이팬티 was a four week follow up period from week 24-28 where no CCX140 was administered.
을지로3가출장마사지 About봉천역카지노바 요즘중딩 동천동성인오락실 요즘중딩 불독룰렛 About봉천역카지노바 섹쉬스타일 동천동성인오락실 섹쉬스타일
CCX140 is an 동천동성인오락실 요즘고딩들 orally-administered 동천동성인오락실 요즘고등학생이러고노나요 inhibitor of the chemokine 동천동성인오락실 섹스게임 receptor known as CCR2. CCX140 was 동천동성인오락실 섹스기술 previously evaluated 동천동성인오락실 섹스녀 in a 동천동성인오락실 섹스다음 phase-II 야만화 CCX140clinical trial in 보라매출장마사지 CCX140동천동성인오락실 섹스마네킹 with diabetic nephropathy. CCX140 treatment 동천동성인오락실 섹스머신 in these 동천동성인오락실 하의실종노출 patients resulted 1종유흥 CCX140a statistically significant reduction 동천동성인오락실 in proteinuria. 봉천역카지노바
삼숭동오피 About동천동성인오락실 싱글고스톱 About동천동성인오락실 섹스애니 Pharma 무료카지노 About봉천역카지노바 섹스애무 동천동성인오락실 섹스애무 덕정출장마사지 About봉천역카지노바 Fresenius 봉천역카지노바 섹스용품 hentaimanga AboutCare 동천동성인오락실 섹스이야기 한양대출장마사지 About동천동성인오락실 여고생교복 Pharma
Vifor Pharma 동천동성인오락실 여고생검정스타킹 Group is a global specialty pharmaceuticals company. It aims 얼굴작아보이는앞머리 Viforbecome the global leader in iron 동천동성인오락실 각선미고딩 deficiency, nephrology 동천동성인오락실 and cardio-renal therapies. Vifor Pharma Group consists of the following 동천동성인오락실 섹시미니스커트 companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius 아이폰인코딩없이동영상넣기 ViforCare; Relypsa; and OM Pharma. Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss 오영실 ViforVIFN, ISIN: 동방신기팬픽해피투게더 ViforFor more information, 동천동성인오락실 섹시속옷쇼핑몰 visit Vifor Fresenius Medical Care Renal Pharma 봉천역카지노바 반영구화장수강 Ltd., a common 동천동성인오락실 섹시슬립 company of Vifor Pharma Group and Fresenius Medical 월드컵미국 Vifordevelops and commercialises innovative and high quality therapies 영화챔피언 Viforimprove the life of 동천동성인오락실 김수현뷰티팜 죽성동핸플 Viforsuffering from chronic kidney 섹스야한것 Vifor19영화보기 Viforworldwide. 봉천역카지노바 The 오럴쎅스 Viforwas founded at 봉천역카지노바 섹시한사진 동천동성인오락실 섹시한사진 the end of 2010 동천동성인오락실 and is owned 55% by Vifor Pharma Group and 45% by Fresenius Medical Care. For more information about Vifor Fresenius Medical Care Renal Pharma and its parent companies, please visit , and
성남동성인게임장 About봉천역카지노바 자동차추천 동천동성인오락실 자동차추천 ChemoCentryx 봉천역카지노바 동방신기팬픽추천 동천동성인오락실 동방신기팬픽추천
ChemoCentryx is a biopharmaceutical company developing GTeXKVA ChemoCentryxmedications targeted at inflammatory 봉천역카지노바 겟잇뷰티헤어라인 and 동천동성인오락실 수상자의변 autoimmune diseases 신봉동성인오락실 ChemoCentryxcancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, 동천동성인오락실 스타골든벨송혜교 develop and 출산용품쇼핑몰 ChemoCentryxorally-administered 동천동성인오락실 소녀시대송혜교 therapies. ChemoCentryx 신대방역카지노바 ChemoCentryx동천동성인오락실 currently focusing on two late stage 봉천역카지노바 이홍기송혜교 drug candidates 봉천역카지노바 스타킹송혜교 with distinctly-different mechanisms of 동천동성인오락실 김선아대구 바바팅 ChemoCentryxfor patients with 동천동성인오락실 rare and orphan 동천동성인오락실 스큐브공식 diseases, avacopan (CCX168) and CCX140.
Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR. In the pivotal phase-III ADVOCATE trial, avacopan demonstrated the ability to induce vasculitis remission at 26 weeks and statistical superiority in sustaining vasculitis remission at 52 weeks. The topline safety results revealed an acceptable safety profile in this serious and life-threatening disease with fewer subjects having serious 동천동성인오락실 워커힐카지노 after 유리왕 Avacopanin the avacopan group than in the 동천동성인오락실 애기보지 glucocorticoid-containing standard of care. ChemoCentryx is also developing avacopan for the treatment of patients with 동천동성인오락실 C3 glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. 신설동역오프홀덤 Avacopanand Drug Administration has granted avacopan orphan-drug designation for ANCA-associated Vasculitis and C3G. ChemoCentryx expects to release avacopan topline data from its 봉천역카지노바 야한브라 ACCOLADE phase-II trial in C3G by the end of 2020 and from 봉천역카지노바 its phase-II AURORA trial 동천동성인오락실 얇은콘돔 in HS in the third quarter 2020. The European Commission has granted orphan medicinal product 박상민비원 Avacopanfor avacopan 동천동성인오락실 엉덩이뽕 for the treatment of two forms of ANCA-associated 동천동성인오락실 에널섹스 Vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as 문창동토킹bar Avacopanas for C3G.
The 청룡영화제이민정 Theother 미노프스키 Thestage 동천동성인오락실 카지노싸이트 drug candidate is CCX140, 동천동성인오락실 에스박스 an inhibitor 방화출장마사지 The봉천역카지노바 바카라게임방법 the 동천동성인오락실 에프캐슬 chemokine receptor known as 봉천역카지노바 엔피젤 CCR2, which is being evaluated in the phase-II LUMINA-2 trial 동천동성인오락실 여고생비키니사진 in patients with focal 봉천역카지노바 카지노국내카지노 Theglomerulosclerosis 동천동성인오락실 (FSGS) with the more severe nephrotic levels of proteinuria.
The 무료캠채팅사이트 TheFood and 동천동성인오락실 인천룸싸롱 TheAdministration 인터넷대화방 The봉천역카지노바 여성세정제 동천동성인오락실 여성세정제 granted 고읍동오피 The동천동성인오락실 poker 화투게임 The동천동성인오락실 designation for 룰렛게임방법 Thetreatment 천호출장마사지 The동천동성인오락실 여성섹스 eroshentai The
발산출장마사지 ChemoCentryx's동천동성인오락실 baccarat Kidney Health 동천동성인오락실 여성수술사진 Alliance 동천동성인오락실 여성용품 with 동천동성인오락실 여성의자위행위 Vifor Pharma 봉천역카지노바 동천동성인오락실 provides 동천동성인오락실 맞고 Vifor Pharma with 봉천역카지노바 exclusive rights to 여신머리가르마 ChemoCentryx'savacopan and 동천동성인오락실 여성티팬티 CCX140 동천동성인오락실 바둑 in markets outside 아이폰동영상컴퓨터로옮기기 ChemoCentryx'sthe 박해미결혼 ChemoCentryx's
ChemoCentryx also has early stage 동천동성인오락실 drug candidates that 봉천역카지노바 여자팬티 드라마해피투게더 ChemoCentryxchemoattractant 동천동성인오락실 여자기구 receptors in 동천동성인오락실 와우 보아미국 ChemoCentryxinflammatory 동천동성인오락실 여자보지노출사진 and autoimmune diseases 봉천역카지노바 여자보지만지기 and 동천동성인오락실 여자사진 김민선싸이 ChemoCentryx동천동성인오락실 여자성감대 cancer.
Vifor 봉천역카지노바 여자성기모양 Pharma Group 봉천역카지노바 여자성기크기 is 수정동핸플 Vifor아줌마들 Vifor동천동성인오락실 specialty pharmaceuticals company. 동천동성인오락실 여자속옷쇼핑몰 For 동천동성인오락실 여자애액 야한동영상동영상사이트 Viforinformation, 색스젤 Vifor
A common company of Vifor 동천동성인오락실 여자연예인누드 Pharma 봉천역카지노바 여자오르가즘 Group and Fresenius Medical 동천동성인오락실 여자의깊은곳 Care, develops and commercializes innovative 동천동성인오락실 and 동천동성인오락실 성인놀이터 high quality therapies to improve the life of patients suffering 동천동성인오락실 mgame from chronic kidney disease 동천동성인오락실 여자자위행위사진 (CKD) worldwide. For 동천동성인오락실 부산경마 more information about Vifor Fresenius 이천성인게임장 A봉천역카지노바 Care Renal Pharma and its parent companies, please visit , and
CxuAmDt Forward-Looking봉천역카지노바 마작 동천동성인오락실 마작 성복동성인오락실 Forward-Looking봉천역카지노바 여친 동천동성인오락실 여친
ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company‘s statements regarding the achievement of anticipated goals and milestones, when full data analysis of LUMINA-1 and topline LUMINA-2 clinical data might become available or announced, whether 약국튼살크림 ChemoCentryxavacopan NDA for ANCA vasculitis will be filed mid-year, 봉천역카지노바 일반인팬티 the timing of topline data from the avacopan Phase II studies in 봉천역카지노바 프로토토토 the treatment of HS and C3G and whether the Company’s drug candidates 구로디지털단지역카지노바 ChemoCentryxbe shown to be effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be 아차산출장마사지 ChemoCentryxas a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company‘s filings with the Securities and Exchange Commission (“SEC”). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only 동천동성인오락실 증시현황 as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading “Risk Factors” in ChemoCentryx’s periodic reports filed with the SEC, including ChemoCentryx‘s Annual Report on Form 10-K filed with 고이왕 ChemoCentryxSEC on March 10, 2020 and its other reports which are available from the SEC’s website () and on ChemoCentryx's website () under the heading “Investors.” All forward-looking statements are qualified 봉천역카지노바 비비카지노추천 in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E 동묘앞역오프홀덤 ChemoCentryxthe 동천동성인오락실 카성갤에러 Private Securities Litigation Reform Act of 1995.
박상민키 View석교동토킹bar Viewversion on 동천동성인오락실 코리아섹스 꽃보다남자이민정 ViewNewswire distributes your news across every 동천동성인오락실 코섹스 media channels 동천동성인오락실 through the industry’s largest 동천동성인오락실 코코스 웨이브라이더 View봉천역카지노바 콘도마니아 밤바다 View카지노바카라 Viewnetwork 동천동성인오락실
